Astria Therapeutics Inc. Common Stock ATXS · Stock Open Astria Therapeutics Inc. Common Stock in new tab
Astria Therapeutics Inc. Common Stock Analysis (ATXS)
Is Astria Therapeutics Inc. Common Stock a good investment? Astria Therapeutics Inc. Common Stock (ATXS) is currently trading at 12.58 USD.
Earnings Schedule: Astria Therapeutics Inc. Common Stock is expected to release its next earnings report on March 10, 2026. The market consensus estimate for Forward EPS is -2.38.
Investor FAQ
Does Astria Therapeutics Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is Astria Therapeutics Inc. Common Stock?
Astria Therapeutics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be March 10, 2026. The company currently has a trailing EPS of -2.14.
Company Profile
Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts. As of January 23, 2026, Astria Therapeutics, Inc. operates as a subsidiary of BioCryst Pharmaceuticals, Inc.
| Split Date | Split Ratio to 1 |
|---|---|
| Dec. 31, 2018 | 1:10 |
| Aug. 20, 2021 | 0.17 |
Community Discussion